Share Price and Basic Stock Data
Last Updated: January 23, 2026, 8:16 pm
| PEG Ratio | 6.37 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Procter & Gamble Hygiene and Health Care Ltd operates in the personal care sector, with a current market price of ₹11,935 and a market capitalization of ₹38,742 Cr. The company recorded sales of ₹3,918 Cr for the fiscal year ending June 2023, reflecting a modest increase from ₹3,901 Cr in the previous fiscal year. Revenue from operations has shown a consistent upward trajectory, with the trailing twelve months (TTM) sales reaching ₹4,326 Cr. Quarterly sales figures indicate fluctuations, with the highest quarterly sales of ₹1,248 Cr recorded in December 2024. The company’s performance in recent quarters, particularly with a resurgence to ₹1,138 Cr in September 2023 after a dip to ₹853 Cr in June 2023, underscores its resilience amidst market challenges. The sales growth trajectory aligns with the broader trends in the personal care sector, where demand for hygiene products remains robust, particularly in the post-pandemic landscape.
Profitability and Efficiency Metrics
Procter & Gamble reported a net profit of ₹827 Cr for the fiscal year ending March 2025, with a net profit margin of 18.86%. The operating profit margin (OPM) stood at 25%, indicating effective cost management and operational efficiency. The company’s return on equity (ROE) was a remarkable 75.7%, and return on capital employed (ROCE) measured at 104%, showcasing the firm’s adeptness at generating substantial returns for shareholders. Additionally, the interest coverage ratio (ICR) of 38.18x reflects strong earnings relative to interest obligations, indicating minimal risk in meeting debt commitments. While the quarterly OPM fluctuated, peaking at 30% in December 2024, the overall profitability metrics remain strong compared to sector norms, where OPM typically ranges between 15-25% for personal care companies. These metrics highlight Procter & Gamble’s robust financial health and operational effectiveness in navigating competitive market dynamics.
Balance Sheet Strength and Financial Ratios
The balance sheet of Procter & Gamble Hygiene and Health Care Ltd reflects a healthy financial position, with total reserves reported at ₹899 Cr and negligible borrowings of ₹2 Cr. This conservative leverage strategy contributes to a low debt-to-equity ratio, enhancing financial stability. The current ratio stood at 1.23, indicating that the company has sufficient short-term assets to cover its liabilities. The price-to-book value (P/BV) ratio was reported at 69.63x, significantly higher than typical industry averages, suggesting that the market has high expectations for the company’s future growth. Furthermore, the cash conversion cycle (CCC) improved to -138 days, indicating efficient management of working capital. The company’s asset turnover ratio of 1.87 suggests effective utilization of assets to generate revenue, reinforcing the balance sheet’s strength. Overall, these financial ratios position Procter & Gamble favorably within the personal care sector, although the high P/BV may indicate that the stock is overvalued compared to its intrinsic worth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Procter & Gamble Hygiene and Health Care Ltd reveals a stable and concentrated ownership structure, with promoters holding 70.64% of the shares. This level of promoter ownership typically instills confidence among investors, as it suggests alignment of interests between management and shareholders. Foreign institutional investors (FIIs) accounted for 1.11% of the ownership, while domestic institutional investors (DIIs) held 16.05%. The public shareholding stood at 12.19%, with a total of 49,997 shareholders. The gradual increase in retail investor participation, reflected by the rising number of shareholders from 40,495 in December 2022 to 49,997 by September 2025, indicates growing investor confidence in the company’s prospects. However, the relatively low FII participation may suggest a cautious outlook on the stock, potentially limiting liquidity and broader market interest. Maintaining a balanced shareholding structure could enhance investor sentiment and support future capital raising efforts.
Outlook, Risks, and Final Insight
The outlook for Procter & Gamble Hygiene and Health Care Ltd remains positive, driven by strong brand equity and a robust product portfolio in the personal care sector. However, several risks could impact its performance, including potential supply chain disruptions and increasing competition from local and international players. The company’s ability to innovate and respond to changing consumer preferences will be critical in sustaining growth. Additionally, fluctuations in raw material prices could affect margins, particularly in a volatile economic environment. On the other hand, the company’s strong profitability metrics, efficient operations, and low debt levels provide a solid foundation for navigating these challenges. Should Procter & Gamble continue to leverage its strengths in brand loyalty and distribution, it may well capitalize on emerging market opportunities. Conversely, failure to adapt to market dynamics could hinder its growth trajectory. Overall, the company is well-positioned to maintain its leadership in the personal care space if it effectively manages these risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,837 Cr. | 272 | 334/190 | 71.0 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 41.6 Cr. | 24.0 | 37.0/22.3 | 81.5 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 120 Cr. | 125 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 560 Cr. | 369 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 9,116 Cr. | 249 | 423/244 | 24.9 | 55.8 | 1.40 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,272.93 Cr | 1,856.86 | 57.41 | 112.70 | 0.76% | 29.21% | 23.91% | 4.94 |
All Competitor Stocks of Procter & Gamble Hygiene and Health Care Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,045 | 1,137 | 883 | 853 | 1,138 | 1,133 | 1,002 | 932 | 1,135 | 1,248 | 992 | 937 | 1,150 |
| Expenses | 831 | 847 | 734 | 638 | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 |
| Operating Profit | 214 | 290 | 149 | 215 | 285 | 310 | 257 | 118 | 290 | 371 | 210 | 266 | 285 |
| OPM % | 20% | 26% | 17% | 25% | 25% | 27% | 26% | 13% | 26% | 30% | 21% | 28% | 25% |
| Other Income | 7 | 9 | 14 | 10 | 16 | 16 | 14 | 7 | 8 | 10 | 19 | 8 | 10 |
| Interest | 1 | 4 | 4 | 3 | 2 | 3 | 22 | -0 | 2 | 7 | 6 | 0 | 4 |
| Depreciation | 14 | 14 | 15 | 15 | 14 | 14 | 15 | 13 | 12 | 10 | 10 | 9 | 9 |
| Profit before tax | 206 | 282 | 146 | 207 | 284 | 309 | 234 | 112 | 285 | 364 | 213 | 265 | 282 |
| Tax % | 25% | 26% | -13% | 27% | 26% | 26% | 34% | 28% | 26% | 26% | 27% | 27% | 26% |
| Net Profit | 154 | 207 | 165 | 151 | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 |
| EPS in Rs | 47.57 | 63.91 | 50.84 | 46.59 | 64.91 | 70.52 | 47.56 | 24.97 | 65.28 | 82.74 | 48.09 | 59.17 | 64.65 |
Last Updated: January 2, 2026, 5:36 pm
Below is a detailed analysis of the quarterly data for Procter & Gamble Hygiene and Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,150.00 Cr.. The value appears strong and on an upward trend. It has increased from 937.00 Cr. (Jun 2025) to 1,150.00 Cr., marking an increase of 213.00 Cr..
- For Expenses, as of Sep 2025, the value is 865.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 671.00 Cr. (Jun 2025) to 865.00 Cr., marking an increase of 194.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 266.00 Cr. (Jun 2025) to 285.00 Cr., marking an increase of 19.00 Cr..
- For OPM %, as of Sep 2025, the value is 25.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Jun 2025) to 25.00%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 265.00 Cr. (Jun 2025) to 282.00 Cr., marking an increase of 17.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Jun 2025) to 26.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Jun 2025) to 210.00 Cr., marking an increase of 18.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 64.65. The value appears strong and on an upward trend. It has increased from 59.17 (Jun 2025) to 64.65, marking an increase of 5.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:45 am
| Metric | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 9m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,051 | 2,334 | 2,275 | 2,320 | 2,455 | 2,947 | 3,002 | 3,574 | 3,901 | 3,918 | 4,206 | 3,374 | 4,326 |
| Expenses | 1,628 | 1,838 | 1,667 | 1,646 | 1,834 | 2,329 | 2,396 | 2,688 | 3,069 | 3,048 | 3,230 | 2,503 | 3,195 |
| Operating Profit | 423 | 495 | 608 | 675 | 622 | 618 | 606 | 886 | 832 | 869 | 976 | 871 | 1,132 |
| OPM % | 21% | 21% | 27% | 29% | 25% | 21% | 20% | 25% | 21% | 22% | 23% | 26% | 26% |
| Other Income | 78 | 64 | 85 | 67 | 18 | 45 | 42 | 38 | 23 | 40 | 47 | 37 | 46 |
| Interest | 5 | 6 | 6 | 10 | 5 | 5 | 6 | 6 | 11 | 11 | 27 | 14 | 16 |
| Depreciation | 35 | 53 | 52 | 60 | 52 | 50 | 48 | 48 | 53 | 58 | 56 | 32 | 39 |
| Profit before tax | 460 | 501 | 636 | 672 | 582 | 607 | 594 | 870 | 790 | 839 | 939 | 862 | 1,123 |
| Tax % | 34% | 31% | 34% | 36% | 36% | 31% | 27% | 25% | 27% | 19% | 28% | 26% | |
| Net Profit | 302 | 346 | 422 | 433 | 375 | 419 | 433 | 652 | 576 | 678 | 675 | 637 | 827 |
| EPS in Rs | 93.04 | 106.63 | 130.16 | 133.31 | 115.40 | 129.12 | 133.42 | 200.79 | 177.37 | 208.91 | 207.95 | 196.11 | 254.65 |
| Dividend Payout % | 30% | 28% | 28% | 292% | 35% | 68% | 79% | 157% | 90% | 89% | 123% | 89% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 3% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | -1% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 68% |
| 3 Years: | 79% |
| Last Year: | 76% |
Last Updated: September 4, 2025, 9:30 pm
Balance Sheet
Last Updated: December 4, 2025, 12:51 am
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Reserves | 970 | 1,196 | 1,619 | 494 | 773 | 877 | 1,125 | 682 | 705 | 914 | 742 | 705 | 899 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 4 | 3 | 2 | 2 |
| Other Liabilities | 505 | 719 | 515 | 634 | 620 | 708 | 671 | 915 | 940 | 1,187 | 1,081 | 1,015 | 1,200 |
| Total Liabilities | 1,508 | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 2,133 |
| Fixed Assets | 240 | 309 | 317 | 286 | 250 | 234 | 206 | 184 | 164 | 170 | 139 | 131 | 166 |
| CWIP | 98 | 39 | 35 | 41 | 21 | 15 | 22 | 38 | 44 | 23 | 28 | 41 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,170 | 1,600 | 1,814 | 834 | 1,154 | 1,368 | 1,600 | 1,411 | 1,475 | 1,945 | 1,692 | 1,583 | 1,953 |
| Total Assets | 1,508 | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 2,133 |
Below is a detailed analysis of the balance sheet data for Procter & Gamble Hygiene and Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
- For Reserves, as of Sep 2025, the value is 899.00 Cr.. The value appears strong and on an upward trend. It has increased from 705.00 Cr. (Mar 2025) to 899.00 Cr., marking an increase of 194.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,200.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,015.00 Cr. (Mar 2025) to 1,200.00 Cr., marking an increase of 185.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,755.00 Cr. (Mar 2025) to 2,133.00 Cr., marking an increase of 378.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 166.00 Cr.. The value appears strong and on an upward trend. It has increased from 131.00 Cr. (Mar 2025) to 166.00 Cr., marking an increase of 35.00 Cr..
- For CWIP, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 27.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,953.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,583.00 Cr. (Mar 2025) to 1,953.00 Cr., marking an increase of 370.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,133.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,755.00 Cr. (Mar 2025) to 2,133.00 Cr., marking an increase of 378.00 Cr..
Notably, the Reserves (899.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 9m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 423.00 | 495.00 | 608.00 | 675.00 | 622.00 | 618.00 | 606.00 | 883.00 | 827.00 | 865.00 | 973.00 | 871.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 15 | 18 | 24 | 21 | 22 | 22 | 20 | 15 | 18 | 20 | 21 | 33 |
| Inventory Days | 53 | 47 | 53 | 71 | 48 | 60 | 68 | 78 | 55 | 48 | 51 | 64 |
| Days Payable | 103 | 148 | 134 | 145 | 156 | 162 | 175 | 237 | 183 | 213 | 193 | 235 |
| Cash Conversion Cycle | -35 | -83 | -57 | -53 | -87 | -79 | -87 | -144 | -110 | -145 | -121 | -138 |
| Working Capital Days | 43 | 4 | 8 | -15 | -23 | -12 | -21 | -39 | -34 | -53 | -32 | -31 |
| ROCE % | 52% | 46% | 45% | 64% | 89% | 73% | 58% | 94% | 110% | 101% | 112% | 104% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Focused Fund | 900,000 | 2.68 | 1148.04 | N/A | N/A | N/A |
| ICICI Prudential Large Cap Fund | 532,050 | 0.87 | 678.68 | N/A | N/A | N/A |
| SBI Equity Hybrid Fund | 430,000 | 0.66 | 548.51 | 430,000 | 2025-04-22 15:16:47 | 0% |
| SBI Midcap Fund | 280,000 | 1.53 | 357.17 | N/A | N/A | N/A |
| Sundaram Mid Cap Fund | 95,691 | 0.91 | 122.06 | 91,606 | 2025-12-15 04:26:01 | 4.46% |
| Franklin India Mid Cap Fund | 88,662 | 0.88 | 113.1 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 69,490 | 2.44 | 88.64 | N/A | N/A | N/A |
| UTI MNC Fund | 49,185 | 2.18 | 62.74 | 38,010 | 2025-12-08 02:04:55 | 29.4% |
| Aditya Birla Sun Life Consumption Fund | 38,899 | 0.76 | 49.62 | N/A | N/A | N/A |
| Sundaram Large and Mid Cap Fund | 34,236 | 0.62 | 43.67 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 196.11 | 207.95 | 208.91 | 177.37 | 200.79 |
| Diluted EPS (Rs.) | 196.11 | 207.95 | 208.91 | 177.37 | 200.79 |
| Cash EPS (Rs.) | 205.96 | 225.36 | 226.89 | 193.66 | 215.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 227.04 | 238.71 | 291.44 | 227.22 | 220.05 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 227.04 | 238.71 | 291.44 | 227.22 | 220.05 |
| Dividend / Share (Rs.) | 175.00 | 255.00 | 185.00 | 160.00 | 315.00 |
| Revenue From Operations / Share (Rs.) | 1039.56 | 1295.66 | 1206.99 | 1201.76 | 1101.09 |
| PBDIT / Share (Rs.) | 279.85 | 315.00 | 280.10 | 263.16 | 284.55 |
| PBIT / Share (Rs.) | 270.01 | 297.59 | 262.12 | 246.87 | 269.87 |
| PBT / Share (Rs.) | 265.61 | 289.34 | 258.62 | 243.42 | 267.99 |
| Net Profit / Share (Rs.) | 196.12 | 207.95 | 208.91 | 177.37 | 200.80 |
| PBDIT Margin (%) | 26.92 | 24.31 | 23.20 | 21.89 | 25.84 |
| PBIT Margin (%) | 25.97 | 22.96 | 21.71 | 20.54 | 24.50 |
| PBT Margin (%) | 25.54 | 22.33 | 21.42 | 20.25 | 24.33 |
| Net Profit Margin (%) | 18.86 | 16.05 | 17.30 | 14.75 | 18.23 |
| Return on Networth / Equity (%) | 86.37 | 87.11 | 71.68 | 78.06 | 91.25 |
| Return on Capital Employeed (%) | 102.66 | 110.03 | 80.85 | 97.31 | 109.87 |
| Return On Assets (%) | 36.27 | 36.31 | 31.72 | 34.24 | 39.92 |
| Asset Turnover Ratio (%) | 1.87 | 2.11 | 2.05 | 2.35 | 2.07 |
| Current Ratio (X) | 1.23 | 1.22 | 1.38 | 1.32 | 1.34 |
| Quick Ratio (X) | 0.98 | 0.99 | 1.18 | 1.05 | 1.04 |
| Inventory Turnover Ratio (X) | 15.10 | 3.47 | 3.74 | 5.22 | 4.97 |
| Dividend Payout Ratio (NP) (%) | 104.53 | 127.43 | 69.40 | 98.66 | 169.32 |
| Dividend Payout Ratio (CP) (%) | 99.53 | 117.59 | 63.90 | 90.36 | 157.79 |
| Earning Retention Ratio (%) | -4.53 | -27.43 | 30.60 | 1.34 | -69.32 |
| Cash Earning Retention Ratio (%) | 0.47 | -17.59 | 36.10 | 9.64 | -57.79 |
| Interest Coverage Ratio (X) | 63.52 | 38.18 | 79.90 | 76.34 | 151.17 |
| Interest Coverage Ratio (Post Tax) (X) | 45.52 | 26.21 | 60.59 | 52.45 | 107.68 |
| Enterprise Value (Cr.) | 43676.26 | 53361.78 | 45454.09 | 42869.00 | 42606.67 |
| EV / Net Operating Revenue (X) | 12.94 | 12.69 | 11.60 | 10.99 | 11.92 |
| EV / EBITDA (X) | 48.08 | 52.19 | 49.99 | 50.19 | 46.13 |
| MarketCap / Net Operating Revenue (X) | 13.09 | 12.83 | 11.85 | 11.15 | 12.11 |
| Retention Ratios (%) | -4.53 | -27.43 | 30.59 | 1.33 | -69.32 |
| Price / BV (X) | 59.92 | 69.63 | 49.08 | 58.99 | 60.58 |
| Price / Net Operating Revenue (X) | 13.09 | 12.83 | 11.85 | 11.15 | 12.11 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Procter & Gamble Hygiene and Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Jun 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 196.11. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.11, marking a decrease of 11.84.
- For Diluted EPS (Rs.), as of Mar 25, the value is 196.11. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.11, marking a decrease of 11.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 205.96. This value is within the healthy range. It has decreased from 225.36 (Jun 24) to 205.96, marking a decrease of 19.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.04. It has decreased from 238.71 (Jun 24) to 227.04, marking a decrease of 11.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.04. It has decreased from 238.71 (Jun 24) to 227.04, marking a decrease of 11.67.
- For Dividend / Share (Rs.), as of Mar 25, the value is 175.00. This value exceeds the healthy maximum of 3. It has decreased from 255.00 (Jun 24) to 175.00, marking a decrease of 80.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,039.56. It has decreased from 1,295.66 (Jun 24) to 1,039.56, marking a decrease of 256.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 279.85. This value is within the healthy range. It has decreased from 315.00 (Jun 24) to 279.85, marking a decrease of 35.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 270.01. This value is within the healthy range. It has decreased from 297.59 (Jun 24) to 270.01, marking a decrease of 27.58.
- For PBT / Share (Rs.), as of Mar 25, the value is 265.61. This value is within the healthy range. It has decreased from 289.34 (Jun 24) to 265.61, marking a decrease of 23.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 196.12. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.12, marking a decrease of 11.83.
- For PBDIT Margin (%), as of Mar 25, the value is 26.92. This value is within the healthy range. It has increased from 24.31 (Jun 24) to 26.92, marking an increase of 2.61.
- For PBIT Margin (%), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 20. It has increased from 22.96 (Jun 24) to 25.97, marking an increase of 3.01.
- For PBT Margin (%), as of Mar 25, the value is 25.54. This value is within the healthy range. It has increased from 22.33 (Jun 24) to 25.54, marking an increase of 3.21.
- For Net Profit Margin (%), as of Mar 25, the value is 18.86. This value exceeds the healthy maximum of 10. It has increased from 16.05 (Jun 24) to 18.86, marking an increase of 2.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 86.37. This value is within the healthy range. It has decreased from 87.11 (Jun 24) to 86.37, marking a decrease of 0.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 102.66. This value is within the healthy range. It has decreased from 110.03 (Jun 24) to 102.66, marking a decrease of 7.37.
- For Return On Assets (%), as of Mar 25, the value is 36.27. This value is within the healthy range. It has decreased from 36.31 (Jun 24) to 36.27, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.87. It has decreased from 2.11 (Jun 24) to 1.87, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has increased from 1.22 (Jun 24) to 1.23, marking an increase of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 0.99 (Jun 24) to 0.98, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.10. This value exceeds the healthy maximum of 8. It has increased from 3.47 (Jun 24) to 15.10, marking an increase of 11.63.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 104.53. This value exceeds the healthy maximum of 50. It has decreased from 127.43 (Jun 24) to 104.53, marking a decrease of 22.90.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 99.53. This value exceeds the healthy maximum of 50. It has decreased from 117.59 (Jun 24) to 99.53, marking a decrease of 18.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is -4.53. This value is below the healthy minimum of 40. It has increased from -27.43 (Jun 24) to -4.53, marking an increase of 22.90.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.47. This value is below the healthy minimum of 40. It has increased from -17.59 (Jun 24) to 0.47, marking an increase of 18.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 63.52. This value is within the healthy range. It has increased from 38.18 (Jun 24) to 63.52, marking an increase of 25.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.52. This value is within the healthy range. It has increased from 26.21 (Jun 24) to 45.52, marking an increase of 19.31.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,676.26. It has decreased from 53,361.78 (Jun 24) to 43,676.26, marking a decrease of 9,685.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.94. This value exceeds the healthy maximum of 3. It has increased from 12.69 (Jun 24) to 12.94, marking an increase of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 48.08. This value exceeds the healthy maximum of 15. It has decreased from 52.19 (Jun 24) to 48.08, marking a decrease of 4.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.09. This value exceeds the healthy maximum of 3. It has increased from 12.83 (Jun 24) to 13.09, marking an increase of 0.26.
- For Retention Ratios (%), as of Mar 25, the value is -4.53. This value is below the healthy minimum of 30. It has increased from -27.43 (Jun 24) to -4.53, marking an increase of 22.90.
- For Price / BV (X), as of Mar 25, the value is 59.92. This value exceeds the healthy maximum of 3. It has decreased from 69.63 (Jun 24) to 59.92, marking a decrease of 9.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.09. This value exceeds the healthy maximum of 3. It has increased from 12.83 (Jun 24) to 13.09, marking an increase of 0.26.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Jun 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Hygiene and Health Care Ltd:
- Net Profit Margin: 18.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 102.66% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 86.37% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 45.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.8 (Industry average Stock P/E: 57.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | P & G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chittranjan Dua | Chairman & Ind.Director |
| Mr. Kumar Venkatasubramanian | Managing Director |
| Mr. Ghanashyam Hegde | Executive Director |
| Mr. Pramod Agarwal | Non Executive Director |
| Mr. Gagan Sawhney | Non Executive Director |
| Ms. Sonali Dhawan | Non Executive Director |
| Mr. Krishnamurthy Iyer | Independent Director |
| Mr. Gurcharan Das | Independent Director |
| Dr. Ashima Goyal | Independent Director |
FAQ
What is the intrinsic value of Procter & Gamble Hygiene and Health Care Ltd?
Procter & Gamble Hygiene and Health Care Ltd's intrinsic value (as of 23 January 2026) is ₹9011.55 which is 25.87% lower the current market price of ₹12,157.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹39,474 Cr. market cap, FY2025-2026 high/low of ₹14,824/11,851, reserves of ₹899 Cr, and liabilities of ₹2,133 Cr.
What is the Market Cap of Procter & Gamble Hygiene and Health Care Ltd?
The Market Cap of Procter & Gamble Hygiene and Health Care Ltd is 39,474 Cr..
What is the current Stock Price of Procter & Gamble Hygiene and Health Care Ltd as on 23 January 2026?
The current stock price of Procter & Gamble Hygiene and Health Care Ltd as on 23 January 2026 is ₹12,157.
What is the High / Low of Procter & Gamble Hygiene and Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Procter & Gamble Hygiene and Health Care Ltd stocks is ₹14,824/11,851.
What is the Stock P/E of Procter & Gamble Hygiene and Health Care Ltd?
The Stock P/E of Procter & Gamble Hygiene and Health Care Ltd is 47.8.
What is the Book Value of Procter & Gamble Hygiene and Health Care Ltd?
The Book Value of Procter & Gamble Hygiene and Health Care Ltd is 287.
What is the Dividend Yield of Procter & Gamble Hygiene and Health Care Ltd?
The Dividend Yield of Procter & Gamble Hygiene and Health Care Ltd is 0.90 %.
What is the ROCE of Procter & Gamble Hygiene and Health Care Ltd?
The ROCE of Procter & Gamble Hygiene and Health Care Ltd is 104 %.
What is the ROE of Procter & Gamble Hygiene and Health Care Ltd?
The ROE of Procter & Gamble Hygiene and Health Care Ltd is 75.7 %.
What is the Face Value of Procter & Gamble Hygiene and Health Care Ltd?
The Face Value of Procter & Gamble Hygiene and Health Care Ltd is 10.0.